Return to study ST000138 main page
MB Sample ID: SA007679
Local Sample ID: | PF0104 |
Subject ID: | SU000157 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Human Inclusion Criteria: | Participants with a baseline fasting glucose < 100 mg/dl and a fasting glucose ? 100 mg/dl at the end of atenolol treatment are considered to have developed IFG. Participants with a baseline fasting glucose < 100 mg/dl and a fasting glucose that remained < 100 mg/dl at the end of atenolol treatment are considered to have not developed IFG. |
Human Exclusion Criteria: | Participants with a fasting glucose ? 100 mg/dl at baseline are excluded from this study. |
Species Group: | Human |
Select appropriate tab below to view additional metadata details:
Sample Preparation:
Sampleprep ID: | SP000154 |
Sampleprep Summary: | - |
Sampleprep Protocol Filename: | Acylcarnitines_LCMSProtocol_SBMRI_ForSECIM_111714.docx |